MoonLake Immunotherapeutics CFO Sells Shares
MoonLake's CFO sold shares in a planned transaction, reflecting insider activity.
Key Points
- On June 18, 2026, MoonLake Immunotherapeutics CFO Matthias Bodenstedt sold 2,794 shares valued at $54,762.
- Shares of NasdaqCM:MLTX traded near $19.19, with a 52-week range between $5.95 and $62.75.
- MoonLake's market cap is approximately $1.41 billion, and analysts have a mean price target of $27.62.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
On June 18, 2026, Matthias Bodenstedt, the Chief Financial Officer of MoonLake Immunotherapeutics, sold 2,794 shares of the company in a planned transaction. The shares were sold at an average price of $19.60, totaling approximately $54,762.
MoonLake Immunotherapeutics Stock Up 49.3%
Shares of NasdaqCM:MLTX are trading near $19.19. MoonLake Immunotherapeutics has a market capitalization of about $1.41 billion. The stock has a 52-week low of $5.95 and a high of $62.75. Its 50-day moving average is around $17.88, while the 200-day moving average is approximately $19.01. The company's current ratio is 8.60, with a quick ratio of 7.89, and a debt-to-equity ratio of 39.68.
$MLTX stock price
Daily closing prices, year to date. Not investment advice.
About MoonLake Immunotherapeutics
MoonLake Immunotherapeutics is a clinical-stage biotechnology firm based in Zug, Switzerland. The company focuses on developing innovative therapies for inflammatory skin and joint diseases. Its flagship product, Sonelokimab, is a novel treatment targeting IL-17A and IL-17F for conditions like hidradenitis suppurativa and psoriatic arthritis. Founded in 2021, MoonLake is led by CEO Dr. Jorge Santos da Silva and employs around 130 people.
Bottom Line
The recent insider sale by MoonLake's CFO is part of a planned transaction, reflecting routine insider activity. Investors often monitor such transactions to gauge insider sentiment. MoonLake's stock has experienced significant volatility, with a wide 52-week trading range. The company's innovative approach in the biotechnology sector continues to draw attention from analysts and investors.
Get MoonLake Immunotherapeutics alerts
New 13F filings, insider trades, and analyst moves on $MLTX, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.